Which non‑steroidal disease‑modifying agents can be used for inflammatory arthritis with minimal risk of leukopenia?

Non-Steroidal DMARDs with Minimal Leukopenia Risk for Inflammatory Arthritis

For inflammatory arthritis, hydroxychloroquine and TNF inhibitors (biologics) are the safest options with minimal leukopenia risk, while sulfasalazine carries moderate risk and methotrexate and leflunomide require careful monitoring. 1

First-Line Conventional Synthetic DMARDs

Hydroxychloroquine - Lowest Leukopenia Risk

• Hydroxychloroquine has the most favorable safety profile regarding leukopenia among conventional synthetic DMARDs
• While EULAR guidelines note it has limited efficacy and is reserved mainly for mild RA 1, it remains an excellent choice when leukopenia risk is the primary concern
• No significant leukopenia association reported in the literature

Sulfasalazine - Moderate Risk

• Leukopenia occurs in 5.6-10% of patients on sulfasalazine 2, 3
• Most episodes are mild and recover spontaneously without drug withdrawal 2
• Serious leukopenia requiring drug withdrawal is rare (0.3-2.5%) 2, 3
• Most episodes occur within the first 24 weeks, but late occurrences require sustained monitoring 3
• EULAR recommends sulfasalazine as an alternative when methotrexate is contraindicated 1

Methotrexate and Leflunomide - Higher Monitoring Required

• Both require regular blood count monitoring due to known myelosuppressive effects
• While EULAR guidelines recommend these as first-line agents 1, they are not optimal choices when specifically avoiding leukopenia risk

Biological DMARDs - Preferred for Leukopenia Avoidance

TNF Inhibitors

• TNF inhibitors (adalimumab, etanercept, certolizumab pegol, golimumab, infliximab) have minimal direct leukopenia risk
• EULAR recommends adding any bDMARD to csDMARD therapy when poor prognostic factors are present 1
• These agents work through different mechanisms than traditional DMARDs and do not typically cause bone marrow suppression

IL-6 Inhibitors

• Tocilizumab and sarilumab are recommended options 1
• Minimal leukopenia risk compared to conventional synthetic DMARDs

Other Biologics

• Abatacept and rituximab are viable alternatives with low leukopenia risk 1

JAK Inhibitors (Targeted Synthetic DMARDs)

• Tofacitinib, baricitinib, filgotinib, and upadacitinib are recommended by EULAR 1
• Important caveat: While effective, JAK inhibitors can cause dose-dependent cytopenias including leukopenia
• These should be used with caution if leukopenia avoidance is the primary goal

Practical Algorithm

When leukopenia risk is the primary concern:

1. Mild disease: Start with hydroxychloroquine alone or in combination
2. Moderate disease: Use sulfasalazine with close monitoring in first 6 months, or proceed directly to biologics
3. Moderate-to-severe disease or poor prognostic factors:
   • Add TNF inhibitor or IL-6 inhibitor to hydroxychloroquine
   • Alternative: Use abatacept or rituximab
4. Avoid or use with extreme caution: Methotrexate, leflunomide, and JAK inhibitors if leukopenia risk is unacceptable

Critical Monitoring Points

• Even with "safer" agents like sulfasalazine, most leukopenia occurs within the first 24 weeks 3
• Complete blood counts should be performed at baseline, then every 2-4 weeks for the first 3 months, then every 3 months thereafter
• Spontaneous recovery is common with sulfasalazine even without drug withdrawal 2
• Drug withdrawal is only necessary for severe or persistent leukopenia

Common Pitfall to Avoid

Do not order broad "rheumatological panels" without clinical suspicion, as this increases false positive results and unnecessary anxiety 4. Target investigations based on specific clinical presentation suggesting inflammatory arthritis (prolonged morning stiffness >1 hour, improvement with movement).